Treatment With 5-AminoLEvuliNic Acid Before Cardiac Surgery
Status:
COMPLETED
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
TALEN is a prospective randomised double-blind placebo-controlled phase 2 study of 5-Aminolevulinic Acid with Sodium Ferrous Citrate (5-ALA-SFC) in adult patients undergoing cardiac surgery on cardiopulmonary bypass (CPB). TALEN aims to identify the optimal biological dose (OBD) of 5-ALA-SFC.
Phase:
PHASE2
Details
Lead Sponsor:
University of Oxford
Collaborators:
Emerald Clinical Inc. SBI Pharmaceuticals Co, Ltd.